Skip to content

US · CTEV · MEDICAL - HEALTHCARE INFORMATION SERVICES

Claritev Corporation (CTEV) intrinsic value and stock valuation

$18.28as of 2026-11-21 · Mkt cap 555.59M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Claritev Corporation DCF and intrinsic value

InvestorsCraft values CTEV with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from CTEV’s statements →

Claritev Corporation Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Healthcare Information Services McLean, VA 22102 claritev.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$965.4M+0.6% 5y CAGRd
20182025
Net income
-$-284.28M
20182025
Free cash flow
-$-12.28M
20182025
Total equity
-$-167.18M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$965.4M$930.6M$961.5M$1.08B$1.12B
Operating income$45.1M-$-1.39B$162M-$-362.73M$386.1M
Net income-$-284.28M-$-1.65B-$-91.7M-$-572.91M$102.1M
EPSd-$-17.3M-$-101.91M-$-5.69M-$-35.87M$6.27M
Operating cash flow$117.3M$107.6M$171.7M$372.4M$404.7M
Capital expenditure-$-129.6M-$-118.12M-$-108.85M-$-89.73M-$-84.59M
Free cash flow-$-12.28M-$-10.51M$62.9M$282.6M$320.1M
Total assets$4.89B$5.15B$6.96B$7.37B$8.22B
Total debt$4.63B$4.54B$4.57B$4.78B$4.93B
Net debt$4.62B$4.52B$4.5B$4.45B$4.74B
Total equity-$-167.18M$84M$1.71B$1.79B$2.34B
Cash and short-term investments$16.8M$16.9M$71.6M$334.1M$185.3M
Income statement
20252024202320222021
Revenue$965.4M$930.6M$961.5M$1.08B$1.12B
Cost of revenue$698.8M$239.4M$235.5M$204.1M$175.3M
Gross profit$266.6M$691.2M$726.1M$875.6M$942.3M
Research and development expenses$0.00$0.00$0.00$0.00$0.00
Selling, general and administrative expenses$221.5M$160.2M$136M$132.1M$151.1M
Other expenses$0.00$1.92B$428.1M$1.11B$405.1M
Operating expenses$221.5M$2.08B$564.1M$1.24B$556.2M
Cost and expenses$920.4M$2.32B$799.5M$1.44B$731.5M
Interest income$1.56M$3.13M$8.23M$3.5M$30K
Interest expense$400.1M$326.4M$333.2M$303.4M$267.5M
Depreciation and amortization$448.5M$436.4M$425.8M$415.7M$412.1M
Ebitda$475.4M-$-1.01B$651.9M$158.3M$815M
Operating income$45.1M-$-1.39B$162M-$-362.73M$386.1M
Total other income/expenses, net-$-418.14M-$-380.78M-$-269.04M-$-198.01M-$-250.67M
Income before tax-$-373.08M-$-1.77B-$-107.06M-$-560.74M$135.5M
Income tax expense-$-88.8M-$-124.88M-$-15.36M$12.2M$33.4M
Net income-$-284.28M-$-1.65B-$-91.7M-$-572.91M$102.1M
Weighted average shares outstanding$16.4M$16.2M$16.1M$16M$16.3M
Weighted average diluted shares outstanding$16.4M$16.2M$16.1M$16M$16.3M
Balance sheet
20252024202320222021
Cash and short-term investments$16.8M$16.9M$71.6M$334.1M$185.3M
Net receivables$138.2M$111.6M$84.8M$78.9M$99.9M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$224.4M$175.5M$193.6M$446.7M$319.3M
Property, plant and equipment, net$340.3M$308.8M$287.1M$257.1M$243.3M
Goodwill and intangible assets$4.29B$4.63B$6.46B$6.65B$7.65B
Long-term investments$0.00$15M$0.00$0.00$0.00
Total non-current assets$4.66B$4.98B$6.77B$6.92B$7.9B
Total assets$4.89B$5.15B$6.96B$7.37B$8.22B
Accounts payable$60.5M$86.3M$19.6M$13.3M$13M
Short-term debt$19.4M$17.6M$18M$19.6M$20.1M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$261.4M$213.8M$166.7M$175.8M$141.9M
Long-term debt$4.61B$4.52B$4.55B$4.76B$4.91B
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$4.79B$4.85B$5.09B$5.4B$5.73B
Capital lease obligations$16.2M$18.2M$21.9M$27.3M$33.6M
Total liabilities$5.06B$5.07B$5.26B$5.58B$5.88B
Common stock$0.00$0.00$0.00$70K$70K
Retained earnings-$-2.43B-$-2.15B-$-499.31M-$-347.8M$225.1M
Accumulated other comprehensive income (loss)-$-4.17M-$-5.06M-$-11.78M$0.00$0.00
Total equity-$-167.18M$84M$1.71B$1.79B$2.34B
Total investments$0.00$15M$0.00$0.00$0.00
Total debt$4.63B$4.54B$4.57B$4.78B$4.93B
Net debt$4.62B$4.52B$4.5B$4.45B$4.74B
Cash flow statement
20252024202320222021
Net income-$-284.28M-$-1.65B-$-91.7M-$-572.91M$102.1M
Depreciation and amortization$445.4M$436.4M$425.8M$415.7M$424.3M
Stock-based compensation$27.8M$26.6M$18M$16.7M$18M
Change in working capital-$-28.87M-$-13.67M-$-21.91M$55.3M-$-46.68M
Accounts receivable-$-26.57M-$-13.2M$4.4M$21M-$-33.83M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-25.86M$42.2M$5.58M$34.4M$7.71M
Net cash provided by operating activities$117.3M$107.6M$171.7M$372.4M$404.7M
Investments in property, plant and equipment-$-129.6M-$-118.12M-$-108.85M-$-89.73M-$-84.59M
Acquisitions, net$0.00$0.00-$-140.94M$0.00-$-149.43M
Net cash used for investing activities-$-121.02M-$-118.12M-$-249.79M-$-104.45M-$-228.38M
Common stock issued$1.74M$0.00$510K$0.00$0.00
Common stock repurchased$0.00-$-10.37M-$-15.22M-$-100M-$-103.79M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$2.36M-$-41.31M-$-180.99M-$-115.74M-$-114.68M
Net change in cash-$-1.33M-$-51.82M-$-259.06M$152.2M$61.6M
Cash at end of period$28.3M$29.7M$81.5M$340.6M$188.4M
Operating cash flow$117.3M$107.6M$171.7M$372.4M$404.7M
Capital expenditure-$-129.6M-$-118.12M-$-108.85M-$-89.73M-$-84.59M
Free cash flow-$-12.28M-$-10.51M$62.9M$282.6M$320.1M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Claritev Corporation

        Claritev Corporation, together with its affiliated companies, provides advanced data analytics and technology-enabled services focused on cost management, payment optimization, and revenue assurance for the healthcare sector across the United States. The company offers a suite of services designed to reduce medical expenses. This includes analytics-driven solutions that utilize sophisticated algorithms and data insights to pinpoint billing overcharges, subsequently assisting with or recommending appropriate reimbursement negotiations. Additionally, their network-focused services secure discounted rates through contracts with healthcare providers and provide outsourced administration for these provider networks. Claritev also specializes in payment and revenue integrity, identifying and removing erroneous or unwarranted charges processed during claims, while simultaneously working to identify, recover, and safeguard underpaid premium amounts. Furthermore, their data and decision science offerings encompass a range of solutions that apply modern data science methodologies—including descriptive, predictive, and prescriptive analytics—to refine benefit plan structures, aid strategic decision-making, enhance patient clinical results, and ultimately lower overall healthcare costs. The company also handles business-to-business healthcare payment processing and other related services. Their diverse clientele includes major national and regional insurance carriers, Blue Cross and Blue Shield organizations, various provider-sponsored and independent health plans, third-party administrators (TPAs), self-insured health plans, property and casualty insurers, bill review firms, and other entities involved in the claims settlement process. Established in 1980 and headquartered in New York, New York, Claritev Corporation was previously known as MultiPlan Corporation before officially adopting its current name in February 2025.

        CEO
        Travis S. Dalton
        Employees
        3K
        Beta
        0.70

        Explore

        Frequently asked questions

        What is the intrinsic value of Claritev Corporation (CTEV)?

        Claritev Corporation (CTEV) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is CTEV undervalued?

        CTEV trades at a price of $18.28 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.